Diego Bagnasco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4148993/publications.pdf

Version: 2024-02-01

74 papers	1,736 citations	279487 23 h-index	301761 39 g-index
74 all docs	74 docs citations	74 times ranked	2326 citing authors

#	Article	IF	Citations
1	Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center. Biomedicines, 2022, 10, 200.	1.4	8
2	Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects. World Neurosurgery, 2022, 160, e267-e277.	0.7	0
3	Specific Therapy for T2 Asthma. Journal of Personalized Medicine, 2022, 12, 593.	1.1	7
4	COVIDâ€19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 871-874.	2.7	33
5	Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respiratory Medicine, 2021, 176, 106261.	1.3	44
6	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	1.6	14
7	Real-life studies in allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 361-367.	1.1	7
8	Personalized medicine and allergen immunotherapy: the beginning of a new era?. Clinical and Molecular Allergy, 2021, 19, 10.	0.8	8
9	Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas. International Forum of Allergy and Rhinology, 2021, 11, 1025-1028.	1.5	2
10	Quick Olfactory Sniffinâ€™ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients. World Allergy Organization Journal, 2021, 14, 100497.	1.6	17
11	Prospective Italian realâ€world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. Clinical and Translational Allergy, 2021, 11, e12067.	1.4	7
12	ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. World Allergy Organization Journal, 2021, 14, 100592.	1.6	17
13	Severe asthma: One disease and multiple definitions. World Allergy Organization Journal, 2021, 14, 100606.	1.6	18
14	Severe asthma, biologicals, and autoâ€injection: Yes, no, may be!. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 444-445.	2.7	6
15	30 years of sublingual immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1107-1120.	2.7	41
16	Evolving phenotypes to endotypes: is precision medicine achievable in asthma?. Expert Review of Respiratory Medicine, 2020, 14, 163-172.	1.0	7
17	Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101874.	1.1	5
18	Biologicals for severe asthma: what we can learn from real-life experiences?. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 64-70.	1.1	8

#	Article	IF	Citations
19	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1460-1463.	2.7	16
20	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	1.6	30
21	Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma. Pulmonary Pharmacology and Therapeutics, 2020, 64, 101966.	1.1	16
22	Biologics for the Treatments of Allergic Conditions. Immunology and Allergy Clinics of North America, 2020, 40, 549-564.	0.7	9
23	Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights . Journal of Asthma and Allergy, 2020, Volume 13, 301-313.	1.5	15
24	Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. Expert Opinion on Pharmacotherapy, 2020, 21, 1283-1286.	0.9	4
25	Minimal clinically important difference for asthma endpoints: an expert consensus report. European Respiratory Review, 2020, 29, 190137.	3.0	72
26	Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study. BioMed Research International, 2020, 2020, 1-4.	0.9	5
27	Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. Expert Review of Respiratory Medicine, 2020, 14, 1019-1026.	1.0	18
28	Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: from eligibility criteria to real practice. Journal of Allergy and Clinical Immunology, 2020, 145, AB17.	1.5	0
29	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respiratory Medicine, 2020, 171, 106080.	1.3	28
30	Biological agents for severe asthma: the evolution of the at-home self-injection approach. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 421-427.	1.1	15
31	Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Review of Clinical Immunology, 2019, 15, 951-958.	1.3	20
32	A case of chronic eosinophilic pneumonia in a patient treated with dupilumab . Therapeutics and Clinical Risk Management, 2019, Volume 15, 869-875.	0.9	49
33	Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review. Expert Review of Respiratory Medicine, 2019, 13, 1087-1094.	1.0	9
34	One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101836.	1.1	57
35	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Realâ€life observation. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2539-2541.	2.7	36
36	New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic . Biologics: Targets and Therapy, 2019, Volume 13, 89-95.	3.0	8

#	Article	IF	Citations
37	Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?. Expert Opinion on Biological Therapy, 2019, 19, 601-606.	1.4	12
38	Shadow cost of oral corticosteroids-related adverse events: AÂpharmacoeconomic evaluation applied to real-life data fromÂtheÂSevereÂAsthma Network in Italy (SANI) registry. World Allergy Organization Journal, 2019, 12, 100007.	1.6	82
39	Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy. World Allergy Organization Journal, 2019, 12, 100086.	1.6	0
40	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulmonary Pharmacology and Therapeutics, 2019, 54, 87-89.	1.1	15
41	Strategies to reduce corticosteroid-related adverse events in asthma. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 61-67.	1.1	28
42	Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 113-120.	1.5	14
43	Severe asthma: one disease many definitions. , 2019, , .		1
44	When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation. European Annals of Allergy and Clinical Immunology, 2019, 51, 135.	0.4	3
45	Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?. Drugs in Context, 2019, 8, 1-11.	1.0	20
46	A phone call shortens waiting list. Interventions to reduce waiting lists and improve the performance of a pneumological clinic. , 2019, , .		0
47	One year of mepolizumab in severe asthma in Italy: efficacy and safety. , 2019, , .		0
48	Switch Omalizumab â€“ Mepolizumab: real life experience. , 2019, , .		0
49	Current insights in allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2018, 120, 152-154.	0.5	20
50	The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials. World Allergy Organization Journal, 2018, 11, 34.	1.6	36
51	Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. BioMed Research International, 2018, 2018, 1-8.	0.9	42
52	Personalizing the approach to asthma treatment. Expert Review of Precision Medicine and Drug Development, 2018, 3, 299-304.	0.4	3
53	Type 2 immunity in asthma. World Allergy Organization Journal, 2018, 11, 13.	1.6	116
54	Importance of inhaler device use status in the control of asthma and COPD: a real life study.. , 2018, , .		1

#	Article	IF	Citations
55	Overlapping biological drugs prescription status: real life in Genoa. , 2018, , .		0
56	Umeclidinium for the treatment of uncontrolled asthma. Expert Opinion on Investigational Drugs, 2017, 26, 761-766.	1.9	7
57	IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulmonary Pharmacology and Therapeutics, 2017, 45, 95-100.	1.1	59
58	Targeting Interleukin-5 or Interleukin-5RÎ±: Safety Considerations. Drug Safety, 2017, 40, 559-570.	1.4	22
59	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Therapeutic Advances in Respiratory Disease, 2017, 11, 40-45.	1.0	27
60	Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?. Frontiers in Immunology, 2017, 8, 242.	2.2	37
61	Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Frontiers in Medicine, 2017, 4, 135.	1.2	65
62	Personalized Medicine in Allergy. Allergy, Asthma and Immunology Research, 2017, 9, 15.	1.1	40
63	New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. Current Pharmaceutical Biotechnology, 2017, 18, 378-383.	0.9	1
64	Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases. Journal of Thoracic Disease, 2016, 8, E716-E725.	0.6	12
65	Biosimilars in allergic diseases. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 68-73.	1.1	11
66	The path to personalized medicine in asthma. Expert Review of Respiratory Medicine, 2016, 10, 957-965.	1.0	10
67	Update on immunotherapy for the treatment of asthma. Current Opinion in Pulmonary Medicine, 2016, 22, 18-24.	1.2	15
68	Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma. Current Allergy and Asthma Reports, 2016, 16, 88.	2.4	29
69	The safety of monoclonal antibodies in asthma. Expert Opinion on Drug Safety, 2016, 15, 1087-1095.	1.0	8
70	Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 186-200.	1.1	152
71	A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. International Archives of Allergy and Immunology, 2016, 170, 122-131.	0.9	164
72	MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. Expert Opinion on Biological Therapy, 2016, 16, 1435-1441.	1.4	1

#	Article	IF	Citations
73	Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. Expert Review of Respiratory Medicine, 2016, 10, 29-38.	1.0	27
74	Multiple Pulmonary Nodules and Unexplained Fever: When the Pulmonologist Fails. International Journal of Immunopathology and Pharmacology, 2014, 27, 309-311.	1.0	0